Chicago, 5 June 2023: Adjuvant osimertinib can improve overall survival (OS) in patients with EGFR-mutated, early-stage non-small-cell lung cancer (NSCLC), according to results from the ADAURA trial presented at the ASCO Annual Meeting 2023.¹

View Details

Related News

• In Sriganganagar and Raisinghnagar, One family is running a dirty business of drugs (22-09-2023)

---

• Four persons involved in cheating in the name of fake pharma company arrested (22-09-2023)

---

• Two patients' health deteriorated after injection in Halat Hospital, Kanpur (22-09-2023)

---

• SEC recommends permission for phase I trial of Cadila Pharma's VZV vaccine (22-09-2023)

---

• Adding preservatives to ayurvedic medicine will change the classification of medicine (22-09-2023)

---

• 50 children fell ill after taking filariasis medicine in Purnia (21-09-2023)

---

• Two smuggling gang youths arrested, one thousand intoxicating pills recovered (21-09-2023)

---

• FSDA Meerut team raided Transport Godown in Hapur to check consignment of Phensedyl (21-09-2023)

---

• NMC gets WFME Recognition for 10 Years (21-09-2023)

---

• Govt approved ₹480 crore to develop talent pool for medical devices sector (21-09-2023)

---